Table 1.
Patient characteristics of the breast cancer cohort.
| Patient characteristics | Total |
|---|---|
| (n = 70) | |
| Gender | |
| female sex, n (%) | 69 (98.6) |
| Age | |
| Age in years, mean–yr. ± SD | 60.3 ± 11.4 |
| (range) | (27 to 87) |
| TNM classification, n (%) | |
| Stage | |
| T0 | 5 (7.1) |
| T1 | 22 (31.4) |
| T2 | 26 (37.1) |
| T3 | 11 (15.7) |
| T4 | 6 (8.6) |
| Node | |
| N0 | 43 (61.4) |
| N1 | 15 (21.4) |
| N2 | 7 (10) |
| N3 | 5 (7.1) |
| Metastasis | |
| M0 | 53 (75.7) |
| M1 | 17 (24.3) |
| Localization of primary tumor | |
| Right | 22 (31.4) |
| Left | 48 (68.6) |
| Histological grading, n (%) | |
| G1 | 5 (7.1) |
| G2 | 36 (51.4) |
| G3 | 28 (40) |
| Unknown | 1 (1.4) |
| ER positive, n (%) | 57 (81.4) |
| PR positive, n (%) | 43 (61.4) |
| Her2 postive, n (%) | 13 (18.6) |
| Treatment, n (%) | |
| Chemotherapy, n, (%) | 33 (47.1) |
| Endocrine based therapy, n (%) | 17 (24.3) |
| HER2-targeted therapy, n (%) | 13 (18.6) |
| Therapy line at the time-point of blood sampling | |
| Adjuvant, n (%) | 20 (28.6) |
| 1st line, n (%) | 16 (22.9) |
| 2nd line, n (%) | 8 (11.4) |
| >2nd line, n (%) | 7 (10) |
n, number; T, tumor; N, lymph node; M, metastasis; %, Percentage; yr., years; SD, Standard deviation; G, grading; ER, estrogen receptor; PR, progesterone receptor.